Person-centered assessment requires recognizing drug-induced toxicity from pharmacokinetic interactions, particularly with narrow therapeutic index drugs. The key patient-specific factors are lithium toxicity symptoms (nausea, tremor, confusion) with elevated lithium level (1.9 mEq/L) and increased creatinine, precipitated by NSAID use which reduces renal lithium clearance. Recognizing toxicity and stopping the NSAID while holding lithium pending urgent evaluation (choice B) is critical to prevent progression to severe toxicity including seizures or coma. Continuing current therapy (A) ignores clear toxicity signs. Increasing lithium (C) would worsen potentially life-threatening toxicity. Changing antidepressants (D) doesn't address the primary lithium-NSAID interaction causing toxicity. The clinical pearl is that NSAIDs significantly increase lithium levels by reducing renal clearance; always screen for NSAID use (prescription and OTC) in lithium-treated patients and educate about avoiding NSAIDs or using alternatives like acetaminophen when possible.

Person-centered assessment in older adults requires identifying and eliminating high-risk medications that increase fall risk and cognitive impairment. The key patient-specific factors are recent falls in an 81-year-old taking multiple Beers Criteria medications: diphenhydramine (anticholinergic), diazepam (long-acting benzodiazepine), and oxybutynin (anticholinergic). Deprescribing diphenhydramine and tapering diazepam (choice B) addresses the primary fall risk factors while transitioning to safer alternatives and non-pharmacologic approaches. Continuing current therapy (A) ignores preventable medication-related falls. Increasing diazepam (C) would worsen sedation and fall risk. Switching to hydroxyzine (D) replaces one sedating antihistamine with another without addressing the benzodiazepine or cumulative anticholinergic burden. The clinical pearl is that polypharmacy review in older adults should prioritize deprescribing CNS-active drugs, particularly anticholinergics and benzodiazepines, which synergistically increase fall risk; always taper benzodiazepines gradually to prevent withdrawal.

Person-centered assessment for newly diagnosed diabetes requires considering glycemic burden, symptoms, and evidence-based treatment algorithms. The key patient-specific factor is the significantly elevated A1c of 9.6% with symptomatic hyperglycemia (polyuria and polydipsia), indicating the need for combination therapy. Starting metformin with planned titration plus basal insulin (choice A) follows current guidelines for symptomatic patients with A1c ≥9%, addressing both insulin resistance and deficiency. Starting glyburide at maximum dose (B) risks hypoglycemia and weight gain without addressing the magnitude of hyperglycemia. Metformin monotherapy without titration (C) is insufficient for this degree of hyperglycemia and delays necessary intensification. Pioglitazone monotherapy (D) causes weight gain and edema, is less effective than metformin, and is not first-line therapy. The clinical pearl is that patients presenting with A1c ≥9% and symptoms often require dual therapy initiation, with metformin plus basal insulin being the preferred approach to rapidly achieve glycemic control while minimizing hypoglycemia risk.

Person-centered assessment and treatment planning for anticoagulation involve identifying drug interactions and monitoring parameters to prevent bleeding or thrombotic events. The key patient-specific factor is the supratherapeutic INR combined with ibuprofen use, which potentiates warfarin's anticoagulant effect and increases bleeding risk in a patient with CKD. Discontinuing ibuprofen and addressing the INR is the best choice for immediate safety, as NSAIDs like ibuprofen are contraindicated with warfarin due to additive bleeding risks. Sertraline with warfarin may increase bleeding but is not the primary issue here and doesn't require immediate cessation; acetaminophen may slightly affect warfarin but increasing dose is inappropriate; amiodarone potentiates rather than reduces warfarin effect, so increasing dose is incorrect. In anticoagulation management, regularly review concurrent medications for interactions and adjust based on INR trends. Prioritize non-NSAID analgesics in patients on warfarin to enhance safety.

Person-centered assessment and treatment planning in heart failure require evaluating medications for potential exacerbation of fluid retention and optimizing therapy for comorbidities. The key patient-specific factor is the presence of HFrEF with new edema, where pioglitazone's fluid retention side effect can worsen heart failure symptoms. Discontinuing pioglitazone and selecting an alternative diabetes agent is the best choice for safety and effectiveness, as thiazolidinediones are contraindicated in symptomatic heart failure. Metformin does not typically cause edema and glyburide increases hypoglycemia risk; carvedilol should not be discontinued abruptly due to rebound risks; spironolactone helps reduce edema and increasing it without assessment is inappropriate. In patients with heart failure and diabetes, prefer agents like SGLT2 inhibitors for dual benefits. Always monitor weight and symptoms to guide de-escalation of offending agents.

Person-centered assessment and treatment planning in asthma involve stepping up therapy based on symptom control and guidelines. The key patient-specific factor is frequent albuterol use indicating poor control, requiring addition of a controller. Starting low-dose ICS is the best choice for effectiveness and safety in moderate persistent asthma. Montelukast monotherapy is insufficient; salmeterol monotherapy risks asthma death; indefinite prednisone has significant side effects. In asthma management, follow GINA guidelines for step therapy. Educate on inhaler technique and trigger avoidance for better outcomes.

Person-centered assessment and treatment planning involve tailoring medication regimens to individual patient needs, considering comorbidities, drug interactions, and administration practices to optimize safety and efficacy. In this case, the key patient-specific factor is the concurrent administration of levothyroxine with iron and calcium supplements along with food, which impairs levothyroxine absorption. The best choice is A because separating levothyroxine from cations like iron and calcium, and administering it on an empty stomach, directly addresses the reduced absorption leading to suboptimal hypothyroidism control, enhancing safety and effectiveness. Choice B is incorrect as alendronate does not significantly reduce iron absorption, and stopping it overlooks the primary issue while potentially compromising osteoporosis management. Choices C and D are less optimal; C wrongly attributes hyperthyroidism to ferrous sulfate when the patient is hypothyroid, and D incorrectly states that calcium increases levothyroxine absorption when it actually decreases it. A key clinical pearl is to always review medication timing and food interactions in patients with hypothyroidism, as evidence shows that cations and food can reduce levothyroxine bioavailability by up to 40%. This framework emphasizes patient education on proper administration to prevent subtherapeutic levels and promote adherence in evidence-based practice.

Person-centered assessment and treatment planning in diabetes therapy emphasize monitoring for class-specific adverse effects like those of SGLT2 inhibitors. The key patient-specific factor is symptoms of polyuria and thirst, indicating potential volume depletion from empagliflozin's diuretic effect. Monitoring for genital infections and volume depletion with counseling is the best choice for safety, aligning with SGLT2 inhibitor risks. Agranulocytosis monitoring is for other classes like clozapine; ototoxicity is for aminoglycosides; monthly ECGs are unnecessary for empagliflozin. In SGLT2 therapy, educate on hydration and sick-day rules to prevent dehydration. Assess renal function periodically to guide continuation.

Person-centered assessment and treatment planning in type 2 diabetes involve tailoring therapy to individual patient preferences, comorbidities, and goals while prioritizing safety and efficacy. The key patient-specific factors here include the preference for oral medication, desire to avoid hypoglycemia, normal renal function, and comorbidities like hypertension and dyslipidemia. Metformin is the best choice as it is the first-line oral agent for type 2 diabetes with a low risk of hypoglycemia, proven cardiovascular benefits, and suitability given normal eGFR. Glyburide is less optimal due to higher hypoglycemia risk, especially in older adults; insulin glargine as monotherapy is injectable and not preferred when orals are desired; pioglitazone may worsen dyslipidemia and cause fluid retention. In similar scenarios, always assess for contraindications like renal impairment before initiating metformin and monitor A1c for effectiveness. Emphasize lifestyle modifications alongside pharmacotherapy for optimal diabetes management.

Person-centered assessment and treatment planning for hypertension side effects involve addressing electrolyte imbalances from diuretics. The key patient-specific factor is hypokalemia causing muscle cramps post-chlorthalidone initiation. Adding potassium supplementation with monitoring is the best choice for safety and continuation of therapy. Increasing chlorthalidone worsens hypokalemia; switching to furosemide may not improve BP control; adding digoxin is inappropriate. In thiazide therapy, routinely check electrolytes and supplement as needed. Educate on potassium-rich foods to prevent recurrence.